Stockreport

AbCellera Biologics: Entering Growth Phase After A Pause [Seeking Alpha]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and AB [Read more]